Humana Inc. (NYSE:HUM) Position Lessened by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. lowered its holdings in shares of Humana Inc. (NYSE:HUM) by 40.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,112 shares of the insurance provider’s stock after selling 757 shares during the period. Stratos Wealth Partners LTD.’s holdings in Humana were worth $294,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in HUM. Dodge & Cox raised its stake in Humana by 106.7% during the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock valued at $2,587,345,000 after acquiring an additional 5,264,045 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Humana by 15.8% during the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after purchasing an additional 1,751,857 shares during the period. Norges Bank acquired a new position in shares of Humana during the 4th quarter valued at $416,202,000. Boston Partners increased its position in shares of Humana by 435.8% during the 4th quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock valued at $279,236,000 after purchasing an additional 893,637 shares during the period. Finally, GAMMA Investing LLC increased its position in shares of Humana by 40,881.1% during the 1st quarter. GAMMA Investing LLC now owns 781,099 shares of the insurance provider’s stock valued at $2,066,790,000 after purchasing an additional 779,193 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Trading Down 2.4%

Shares of HUM opened at $221.99 on Wednesday. Humana Inc. has a 12-month low of $212.45 and a 12-month high of $406.46. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $26.79 billion, a price-to-earnings ratio of 15.70, a P/E/G ratio of 1.56 and a beta of 0.44. The stock’s 50-day moving average price is $236.58 and its 200 day moving average price is $257.89.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping the consensus estimate of $10.07 by $1.51. The business had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. Humana had a return on equity of 14.47% and a net margin of 1.42%. Humana’s revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the business earned $7.23 EPS. As a group, research analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.59%. The ex-dividend date is Friday, June 27th. Humana’s dividend payout ratio is 25.04%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on HUM. Barclays set a $268.00 target price on Humana and gave the stock an “equal weight” rating in a report on Thursday, June 12th. Wall Street Zen cut Humana from a “buy” rating to a “hold” rating in a report on Saturday. Robert W. Baird lifted their target price on Humana from $270.00 to $300.00 and gave the stock a “neutral” rating in a report on Tuesday, April 15th. Oppenheimer lifted their target price on Humana from $300.00 to $310.00 and gave the stock an “outperform” rating in a report on Thursday, May 1st. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $290.00 target price on shares of Humana in a report on Thursday, May 1st. Seventeen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $280.76.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.